Orchestra Biomed Holdings, INC 10-Q quarterly reports

Orchestra BioMed Holdings, Inc. reported its Q2 2026 financial results, showing a significant increase in net loss driven by higher R&D expenses and substantial interest costs, though a gain from a strategic investment provided some offset.

Orchestra BioMed reports increased net losses in Q3 2025, but secures significant new financing and initiates a pivotal clinical trial for Virtue SAB, while terminating its Terumo agreement.

Orchestra BioMed Holdings, Inc. reported increased Q2 losses and R&D expenses but secured $76.2 million in new capital and extended debt amortization, providing funding into late 2027.

Orchestra BioMed Holdings reports increased revenue but a larger net loss in Q1 2025, while also expressing substantial doubt about its ability to continue as a going concern due to insufficient capital.

Orchestra BioMed Holdings announced its Q3 2024 financial results, highlighting a revenue increase and a new $50 million loan facility, while also noting ongoing research and development expenses.

Orchestra BioMed Holdings reported a net loss of $29.4 million for the first six months of 2024, with ongoing investments in research and development.

Orchestra BioMed Holdings reported a net loss of $13.5 million for the first quarter of 2024, while highlighting advancements in its BackBeat CNT and Virtue SAB programs.